Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access

Author:

Barszczewska Olga,Chami Ralph,Piechota Anna

Abstract

The EU approved the first biosimilar drug in 2006. By 2017, the EU had authorized the highest number of biosimilars worldwide, acquiring considerable experience in their use and safety. In May 2019, the European Medicines Agency (EMA) search engine showed 54 authorized biosimilars. Biosimilars reduce public expenditure; however, the discussion about their potential disadvantages is still ongoing. Each country adopts different regulations on the interchangeability, switching, and substitution of a reference medicine by its biosimilar, since the EMA does not regulate this issue. Additionally, each nation has a unique reimbursement system, which results in significant differences in patients’ access to biosimilars. The importance of securing a higher availability of these cheaper versions of biological drugs is well-recognized. The better the access to these biosimilars is, the lower the overall drug expenditure and need for rationing would be, and therefore the better treatment results. The aim of this paper is to compare selected aspects of reimbursement and access to the EMA authorized biosimilar medicines in two countries – France and Poland. The stated drug policy goal of both countries is to significantly improve biosimilar implementation in the coming years. The research is based on an analysis of four main sources: the EMA biosimilars database, the Polish reimbursement list published by the Polish Ministry of Health, and two French reimbursement databases published by the French Ministry of Health. An additional literature review was conducted. The expected results concentrate on differences in the number of reimbursed biosimilars, the average time between EMA authorization and country reimbursement decision date, and the availability of biosimilars registered outside of the centralized (EMA) procedure. These findings could identify areas of improvement and help with discussions on how to optimize the reach of biosimilars, as well as improve French-Polish collaboration on this matter.

Publisher

Uniwersytet Lodzki (University of Lodz)

Subject

General Medicine

Reference21 articles.

1. DemosEUROPA (2015), Leki biologiczne w polskim systemie ochrony zdrowia, DemosEUROPA – Centrum Strategii Europejskiej. Available at: https://www.infarma.pl/assets/files/innowacje/Leki_biologiczne_w_polskim_systemie_zdrowia_Raport_demosEUROPA.pdf (accessed: 2.07.2019)

2. European Medicines Agency and the European Commission (2017), Biosimilars in the EU. http://dx.doi.org/10.1201/9781315119878-15

3. EY Life Sciences (2018), Global biosimilar policy comparison, EY Life Sciences, pp. 50–59. Available at: https://www.eyadvisory.co.jp/services/documents/pdf/global-biosimilar-policy-comparison-report_final.pdf (accessed: 3.07.2019)

4. Gamez-Belmonte, R. et al. (2018) Biosimilars: Concepts and controversies, “Pharmacological Research”, Elsevier Ltd, Vol. 133, pp. 251–264. http://dx.doi.org/10.1016/j.phrs.2018.01.024

5. Gronde, T. van der, Uyl-de Groot, C.A. and Pieters, T. (2017), Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks, “PloS One”, http://dx.doi.org/10.1371/journal.pone.0182613

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3